Following the exciting 2022 in-person Communiqué Awards, we are pleased to offer our readers a selection of case studies that ...

As we enter a new decade, new discoveries in healthcare and the advantages and practical assistance new technologies can offer us mean that we are looking towards a bigger and brighter future. However ...

After months of desperate hope and the huge cost of living with the virus, help finally appeared on the horizon in early December 2020 with the news that Pfizer/BioNTech’s COVID-19 vaccine had been ...

As we herald the start of 2019 with the first of the Communiqué Directory’s two issues for the year, in addition to the extreme uncertainty that we are facing concerning all the possible options that ...

This year, the responsibility to meet the highest standards of evidence and regulatory compliance in pharma seems more important than ever. We are bombarded with news and information 24 hours a day ...

A lot has changed for the better over the past few years. As Mike Dixon, the author of this issue’s foreword, writes: “There has been a renewed and reinvigorated focus on diversity, equity and ...

As the high calibre of the Communiqué Awards entries clearly reflects, industry innovators are constantly striving to raise the bar and achieve real change as the level of excellence in communications ...

Celebrating the first virtual Communiqué Awards! In a year marked by unprecedented change and a new necessity for adaptability, the Communiqué Awards held its first virtual awards event on 2 July, ...

Celebrating a return to the live Communiqué Awards! In 2020, a year marked by unprecedented change and a new necessity for adaptability, for the first time, the Communiqué Awards were held virtually ...

They say that 40 is the new 30, but for the Communiqué directory 40 means 40. That is to say, 40 issues (and counting) that combine leading agencies with analysis, best practice and opinion to produce ...

Pfizer’s Hympavzi (marstacimab) has been approved by the European Commission (EC) to treat haemophilia A or B in adult and ...